The Medical Letter on Drugs and Therapeutics
Two New Drugs for Renal Cell Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 2/22/07: Corrected reference number in Dosage and Cost section.

Sunitinib (Sutent – Pfizer) and sorafenib (Nexavar – Bayer), two oral tyrosine kinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma (RCC). Sunitinib is also approved for use in patients with gastrointestinal stromal tumor (GIST) who are not responding to or are intolerant of standard therapy with imatinib (Gleevec).

DRUGS FOR ADVANCED RCC — The cytokines interleukin- 2 (IL-2) and interferon alfa have been used to treat advanced RCC. Interferon alfa has produced a response rate of 14% with a median duration of 6 months. High-dose IL-2 has produced a response rate of 21%, with substantial toxicity (capillary leak syndrome), but with a median duration of 54 months.1

SUNITINIB — Mechanism of Action – Sunitinib inhibits a variety of transmembrane receptor tyrosine kinases including vascular endothelial ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Renal Cell Carcinoma
Article code: 1255b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian